|
|
|
|
 |
 |
GlaxoSmithKline Press Releases |
 |
|
|
|
|
31st December, 2004
GlaxoSmithKline's response to the Asian disaster
GlaxoSmithKline's response to the Asian disaster
As a first line response to the disaster caused by the tsunami on December 26, medicines donated by GlaxoSmithKline (GSK) are being airlifted to the affected countries across Asia ...
|
22nd December, 2004
GlaxoSmithKline receives European approval for Kivexa , new once-daily HIV medication combining two antiretrovirals in one tablet
GlaxoSmithKline receives European approval for Kivexa, new once-daily HIV medication combining two antiretrovirals in one tablet
Not for distribution in the US
Issued : Wednesday 22 December 2004, London, UK
GlaxoSmithKline (GSK) announced today it has received marketing approval from the European Commission for Kivexa™, a new HIV medication ...
|
15th December, 2004
Study shows GlaxoSmithKline's ReQuip (ropinirole HCl) tablets effectively treats symptoms of primary Restless Legs Syndrome and improves sleep and quality of life in patients
Study shows GlaxoSmithKline's ReQuip (ropinirole HCl) tablets effectively treats symptoms of primary Restless Legs Syndrome and improves sleep and quality of life in patients
Research Triangle Park, NC (December 15, 2004) – Study results published today in the journal Movement Disorders show that Requip®(ropinirole HCl) Tablets effectively treats the symptoms of primary Restless Legs Syndrome (RLS) as assessed by improvements in symptoms, over 12 weeks ...
|
15th December, 2004
Viral suppression of once daily Lexiva plus Ritonavir sustained over 120 weeks in ART-naïve subjects, according to study presented at DART
Viral suppression of once daily Lexiva plus Ritonavir sustained over 120 weeks in ART-na subjects, according to study presented at DART
Montego Bay, Jamaica – Dec. 15, 2004 – The protease inhibitor (PI) Lexiva® (fosamprenavir calcium) plus ritonavir (Lexiva/r) dosed once daily (QD) demonstrated sustained viral suppression and safety over 120 weeks, according to data presented here today at the Frontiers in Drug Development for Antiretroviral Therapies (DART) conference ...
|
13th December, 2004
GlaxoSmithKline acquires full marketing and development rights for Bexxar worldwide
GlaxoSmithKline acquires full marketing and development rights for Bexxar worldwide
Philadelphia, PA December 13, 2004 — GlaxoSmithKline today announced that it has reached an agreement with Corixa Corporation to acquire worldwide rights and responsibilities related to the manufacturing, development and commercialization of the Bexxar® therapeutic regimen ...
|
10th December, 2004
GlaxoSmithKline plc - Board & directorate changes
GlaxoSmithKline plc - Board & directorate changes
Issued – Friday 10 December 2004, London - LSE
GlaxoSmithKline plc (GSK) announces today that Sir Peter Job has decided to retire from the Board with effect from 31st December 2004 after seven years service with GSK and Glaxo Wellcome plc ...
|
8th December, 2004
Landmark survey reveals asthma in children remains significantly out of control in the United States
Landmark survey reveals asthma in children remains significantly out of control in the United States
Asthma Control in children falls far short of national treatment goals
New York, NY (December 8, 2004) — Findings from one of the nation’s largest and most comprehensive surveys about children and asthma to date, Children and Asthma in America, reveal that more than half (54%) of all children with asthma had a severe asthma attack in the past year and more than one quarter (27%) had an asthma attack so bad they thought their life was in danger ...
|
7th December, 2004
GlaxoSmithKline to provide up to 4 million emergency doses of flu vaccine to US market
GlaxoSmithKline to provide up to 4 million emergency doses of flu vaccine to US market
Issued — Tuesday 7 December 2004, London, UK / Philadelphia, US
GlaxoSmithKline today announced that it will ship up to 4 million doses of its flu vaccine, Fluarix, to the United States beginning immediately and continuing through mid-January 2005 ...
|
6th December, 2004
New drug application submitted to FDA for intravenous injection of Boniva ™
New drug application submitted to FDA for intravenous injection of Boniva™
FOR IMMEDIATE RELEASE
Would be First IV Bisphosphonate Treatment for Osteoporosis
NUTLEY, N.J. and RESEARCH TRIANGLE PARK, N.C ...
|
3rd December, 2004
GlaxoSmithKline presents new data on an investigational agent which increases platelet counts, SB497115, at the American Society of Hematology meeting
GlaxoSmithKline presents new data on an investigational agent which increases platelet counts, SB497115, at the American Society of Hematology meeting
PHILADELPHIA, December 3, 2004 – GlaxoSmithKline (NYSE: GSK) today announced that data on its investigational platelet producing agent, SB-497115, will be presented at the 2004 annual meeting of the American Society of Hematology (ASH) in San Diego, California ...
|
|
|
|
Next 10 » |
|
|
|
|
